Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 15/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14334189 | 1.00 | TRPM8 (0.51) | TRPM8TLR7TRPV1CES2CES1 | |
| Hydrochloric Acid SCHEMBL14333255 | 0.98 | TRPM8 (0.51) | TRPM8TLR7 | |
| Hydrochloric Acid SCHEMBL14333110 | 0.98 | TRPM8 (0.51) | TRPM8TLR7 | |
| Hydrochloric Acid SCHEMBL14333256 | 0.98 | TRPM8 (0.51) | TRPM8TLR7 | |
| Hydrochloric Acid SCHEMBL14333112 | 0.98 | TRPM8 (0.51) | TRPM8TLR7 | |
| SCHEMBL14333635 | 0.84 | TRPM8 (0.55) | TRPM8TRPV1 | |
| SCHEMBL14407057 | 0.84 | TRPM8 (0.43) | TRPM8TLR7TRPV1 | |
| SCHEMBL14333634 | 0.84 | TRPM8 (0.55) | TRPM8TRPV1 | |
| SCHEMBL15023620 | 0.84 | TRPM8 (0.43) | TRPM8TLR7TRPV1 | |
| SCHEMBL14407028 | 0.83 | S1PR1 (0.36) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2723718-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012177896-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885TLR7 1143/4885TRPV1 7/4885 |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885TLR7 1143/4885TRPV1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.